1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Elanco Animal Health, Inc.

Elanco Animal Health, Inc.

5EA.DE
Elanco Animal Health, Inc.DE flagDeutsche Börse
21.41
EUR
-0.13
- -
10.64BMarket Cap
Elanco Animal Health, Inc.
5EA.DE
(Deutsche Börse)

Recent

price

21.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.17
8.18
8.11
9.78
8.32
7.41
9.78
9.03
8.97
8.99
9.5
9.85
Revenue per Share
-0.59
-0.13
-0.87
0.28
0.18
-1.3
-0.99
-0.16
-2.5
0.68
-0.47
-0.49
Basic EPS, GAAP
-0.26
0.13
0.16
1.12
0.07
-0.8
0.59
0.55
0.24
0.77
0.57
0.63
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
0.05
0.23
-1.08
-2.01
-2.16
-4.65
-3.95
-4.4
-4.28
Book Value per Share
- -
5.14
6
-0.85
0.2
-9.37
-8.73
-7.26
-6.84
-4.05
-3.3
-2.92
Tangible Book Value per Share
356
356
356
314
369
441
487
488
492
494
496
497
Basic Weighted Avg Shares
2,909
2,914
2,889
3,067
3,071
3,271
4,764
4,411
4,417
4,439
4,715
4,893
Sales/Revenue/Turnover
0.19
9.72
4.93
10.23
12.08
-2.51
6.38
8.71
7.38
5.65
5.34
6.13
Operating Margin (%)
237
254
318
296
314
517
716
682
694
662
680
691
Depreciation Expense
-211
-48
-311
86
68
-574
-483
-78
-1,231
338
-232
-242
Net Income, GAAP
- -
- -
- -
24.19
12.82
- -
- -
- -
- -
30.74
- -
90.48
Effective Tax Rate (%)
-7.25
-1.64
-10.75
2.82
2.21
-17.55
-10.14
-1.77
-27.87
7.61
-4.92
-4.95
Profit Margin (%)
- -
1,328
1,481
1,534
1,555
1,340
1,627
1,577
2,166
1,900
1,861
1,922
Working Capital
- -
- -
- -
2,443
2,330
5,572
6,025
5,448
5,736
4,277
3,943
3,918
LT Debt
- -
7,028
7,780
5,198
5,547
8,476
7,508
7,289
6,223
6,096
6,547
6,500
Total Equity
- -
- -
- -
3.08
4.16
- -
- -
- -
- -
1.55
- -
- -
Return on Invested Capital (%)
- -
- -
- -
8.75
5.55
- -
- -
- -
- -
17.1
- -
-9.55
Return on Capital (%)
- -
- -
- -
1,054.88
135.05
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
62
74
73
LT Borrowings
3,962
3,943
3,918
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
497
497
499
Market Capitalization
9,935
11,308
11,919

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,493
3,458
3,584
Cash, Cash Equivalents & STI
505
545
428
Accounts Receivable, Net
894
873
1,084
Inventories
1,708
1,737
1,717
Total Current Liabilities
1,455
1,597
1,662
Payables & Accruals
352
368
372
ST Debt
62
74
73
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4.72%
7.4%
Free Cash Flow
-114.61%
-8.87%
-25.26%
Net Income, GAAP
46.04%
216.48%
-168.64%
Sales/Revenue/Turnover
5.72%
9.02%
6.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,205
1,184
1,030
1,020
4,439
2025
1,193
1,241
1,137
1,144
4,715
2026
1,371
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.1
0.74
-0.02
0.68
2025
0.14
0.02
-0.07
- -
-0.47
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Magle Chemoswed Holding AB (publ) (MAGLE.ST)
Adynxx, Inc. (ADYX)
Rigel Pharmaceuticals, Inc. (RIGL)
Heidelberg Pharma AG (HPHA.DE)
Nabriva Therapeutics plc (NBRVF)
Kuros Biosciences AG (CSBTF)
Business
Elanco Animal Health Incorporated Elanco Animal Health Incorporated is a global leader in animal health that develops, manufactures and markets innovative pharmaceutical products and services to prevent and treat diseases in farm animals and companion pets; its core offerings span farm animal solutions including vaccines, antibiotics, parasiticides, growth promoters and feed additives for beef, dairy, pork, poultry and aquaculture operations, as well as pet health products such as parasiticides (e.g., Credelio Quattro), dermatology treatments, pain therapeutics and vaccines targeting veterinarians, pet owners and farmers. Founded in 1954 and headquartered in Indianapolis, Indiana, following the opening of its new global headquarters campus in October 2025, the company operates in over 90 countries with approximately 9,400 employees worldwide and focuses on two primary segments—farm animal health and pet health—delivering value through data analytics, training and sustainability initiatives like livestock methane reduction via Bovaer. In recent developments, Elanco completed the $1.3 billion sale of its aqua business to Merck Animal Health in mid-2024 to prioritize higher-growth areas in pet therapeutics and livestock sustainability, raised its full-year 2025 outlook and innovation revenue targets in the third quarter earnings amid six potential U.S. blockbuster product launches by year-end including Zenrelia and Credelio Quattro, and continues advancing its pipeline in next-generation parasiticides, monoclonal antibodies and chronic pet conditions.